OCUL Overview
Upcoming Projects (OCUL)
-
Advancing Treatment Paradigms in Glaucoma: The Impact and Innovation of PAXTRAVA in Redefining Intraocular Pressure Management
Ticker: OCUL
Execute By: May 31, 2024
Executed Projects (OCUL)
Expired Projects (OCUL)
-
Discussing Ocular Therapeutix’s OTX-TKI in treating wet age-related macular degeneration
Ticker: OCUL
Execute By: Mar 31, 2023
Upcoming & Overdue Catalysts (OCUL)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (OCUL)
-
Ocular Therapeutix(OCUL) Releases Phase 1 Trial Interim Data for OTX-TKI (axitinib intravitreal implant) in Treating Neovascular AMD
Ticker: OCUL
Occurred on: Feb 13, 2021 -
Ocular (OCUL) Announces Topline Results of Phase 3 Clinical Trial of DEXTENZA in Ocular Itching Associated with Allergic Conjunctivitis
Ticker: OCUL
Occurred on: Apr 28, 2020 -
Phase 3 data for DEXTENZA in Post-surgical ocular inflammation and pain due 4Q 2016
Ticker: OCUL
Occurred on: Nov 14, 2016 -
Ocular Therapeutix Provides Update on NDA for DEXTENZA for the Treatment of Post-Surgical Ocular Pain
Ticker: OCUL
Occurred on: Aug 03, 2016 -
Ocular Therapeutix Receives Complete Response Letter from FDA for its NDA for DEXTENZA for the Treatment of Post-Surgical Ocular Pain
Ticker: OCUL
Occurred on: Jul 25, 2016 -
Ocular Therapeutix Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension
Ticker: OCUL
Occurred on: Feb 16, 2016
Strategic Initiatives (OCUL)
-
Ocular Therapeutics (OCUL) and Regeneron (REGN) Agree to Develop a Sustained-Release Formulation of Aflibercept for Wet Age-Related Macular Degeneration (Wet AMD)
Tickers: OCUL, REGN
Announcement Date: Oct 13, 2016
